Autonomix Medical, INC

Autonomix Medical, Inc. disclosed a cash balance of approximately $5.1 million as of July 28, 2026, with 971,043 shares of common stock outstanding.

Autonomix Medical announced a warrant inducement agreement to exercise existing warrants, raising approximately $2.6 million and issuing new warrants.

Autonomix Medical, Inc. announced it has regained compliance with Nasdaq's minimum $1.00 bid price requirement, closing the deficiency matter.

Autonomix Medical is consolidating its common stock through a 1-for-21 reverse split effective June 24, 2026, to restructure its equity and maintain market compliance.

Autonomix Medical, Inc. received a deficiency letter from Nasdaq for failing to maintain the minimum $1.00 bid price requirement for its common stock.

Autonomix Medical, Inc. announced new subgroup clinical data from its PoC study demonstrating rapid, durable, and meaningful pain relief in pancreatic cancer patients across all disease stages.

Autonomix Medical, Inc. reported increased net losses and significant cash burn in its latest quarterly filing, raising substantial doubt about its ability to continue as a going concern, while also facing a Nasdaq delisting notice.

Autonomix Medical, Inc. reported a significant increase in net loss for the quarter ended September 30, 2025, while advancing its clinical programs and securing new financing agreements.

Autonomix Medical, a pre-revenue medical device company, reported increased losses and significant cash burn, raising substantial doubt about its ability to continue as a going concern despite positive clinical trial progress and patent grants.

Autonomix Medical, a clinical-stage medical device company, announced its Q3 2025 financial results, detailing a recent public offering and a reverse stock split.

Autonomix Medical's Q2 2024 report highlights increased operating expenses, a reverse stock split, and ongoing development of their neural sensing and treatment technology.

Autonomix Medical's Q1 2024 results show a widened net loss of $2.7 million, primarily due to increased general and administrative and research and development expenses, as the company progresses with its technology development.

Autonomix Medical, Inc. filed an amendment to its 2026 Annual Report to include required Part III disclosures regarding governance and executive compensation.

Autonomix Medical, Inc. filed its Form 10-K for the fiscal year ended March 31, 2026, outlining its capital stock, warrant details, and ongoing development efforts.

Autonomix Medical, Inc. filed an amendment to its annual report to provide comprehensive details on executive compensation, corporate governance, and related party transactions for the fiscal year ended March 31, 2025.

Autonomix Medical, a development-stage medical device company, reported a $50.4 million accumulated deficit and negative cash flows, raising substantial doubt about its ability to continue as a going concern, despite positive early clinical trial results for its novel nerve-sensing and ablation technology.

Autonomix Medical has filed an amendment to its annual report to include previously omitted information regarding directors, executive compensation, and corporate governance.

Autonomix Medical, Inc.'s 2024 annual report highlights its development-stage status, ongoing financial challenges, and progress in its innovative neural sensing and treatment technology.

Autonomix Medical's CEO, Bradley Hauser, had his 45,000 stock options cancelled by mutual agreement, receiving three months of severance.

Autonomix Medical Director Christopher Capelli cancelled 3,750 stock options without consideration, following a 1-for-20 reverse stock split.

Autonomix Medical Director Walter Klemp's stock option for 8,773 shares was cancelled by mutual agreement, with no consideration received.

Autonomix Medical Director Lori Bisson cancelled 65,542 stock options without receiving any consideration, following a 1-for-20 reverse stock split.

Autonomix Medical's CFO, Trent N. Smith, cancelled stock options for 32,655 shares in exchange for three months of additional severance.

David Andrew Robins, a director of Autonomix Medical, Inc., reported the acquisition of derivative securities, specifically warrants, on June 18, 2024.

Autonomix Medical, Inc. announced its annual stockholder meeting to vote on director elections, auditor ratification, a reverse stock split, an equity incentive plan, and a significant stock issuance.

Autonomix Medical, Inc. will hold its Annual Meeting to vote on a reverse stock split, an expanded equity incentive plan, and a $15 million capital raise agreement with Lincoln Park Capital.

Autonomix Medical, Inc. is holding its annual meeting of stockholders on October 17, 2024, to elect directors, ratify the appointment of auditors, and approve a potential reverse stock split.

Autonomix Medical is holding its annual meeting on October 17, 2024, seeking stockholder approval for a reverse stock split, the election of five board nominees, and the ratification of its independent auditor.

Autonomix Medical, a development-stage medical device company, filed an S-1 registration statement for the resale of up to 2.5 million shares, including a $15 million committed equity financing facility with Lincoln Park Capital, as it progresses its neuromodulation technology for pain management and other disorders.

Autonomix Medical, Inc. details the terms and conditions for its Series B Common Stock Purchase Warrants, including exercise price, limitations, and adjustment provisions.

Autonomix Medical, a development-stage medical device company, filed an S-1 registration statement for the resale of common stock underlying warrants, highlighting positive clinical trial results for its pain management system while facing significant going concern doubts.

Autonomix Medical is launching a firm commitment public offering to raise up to $9 million for clinical trials and development of its nerve-sensing and treatment technology.

Autonomix Medical launches a unit offering to raise capital for clinical trials and development of its innovative nervous system disorder treatment platform.

Several investment funds and their principals have reported divesting their entire beneficial ownership in Autonomix Medical, Inc., reducing their stake to 0%.

BioStar Ventures III, L.P. and its general partner have reduced their beneficial ownership in Autonomix Medical, Inc. to 4.3% of common stock.

CVI Investments, Inc. and Heights Capital Management, Inc. have jointly disclosed a beneficial ownership of 4.9% in Autonomix Medical, Inc., totaling 116,087 shares.